Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.54 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.54 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | FNTA | P49354 | 1/20 | 0.42 |
| ▸ | FNTB | P49356 | 1/20 | 0.42 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30867042 | 1.00 | GPR84 (0.54) | GPR84FFAR1FFAR4CAMK2AMAOA | |
| SCHEMBL2026108 | 0.98 | GPR84 (0.50) | GPR84FFAR1FFAR4CAMK2AMAOA | |
| SCHEMBL1317874 | 0.90 | — | — | |
| SCHEMBL18045569 | 0.90 | MAOA (0.50) | GPR84FFAR1FFAR4MAOAMAOB | |
| SCHEMBL18045567 | 0.90 | MAOA (0.50) | GPR84FFAR1FFAR4MAOAMAOB | |
| SCHEMBL10606865 | 0.88 | CAMK2A (0.48) | GPR84FFAR1FFAR4CAMK2AMAOA | |
| Hydrochloric Acid SCHEMBL28067283 | 0.88 | CAMK2A (0.48) | GPR84FFAR1FFAR4CAMK2AMAOA | |
| SCHEMBL18045572 | 0.87 | MAOA (0.46) | CAMK2AMAOAMAOBPRMT1LTA4H | |
| SCHEMBL29589880 | 0.86 | CAMK2A (0.46) | GPR84FFAR1FFAR4CAMK2AMAOA | |
| 1,3-Propanediol SCHEMBL7534849 | 0.86 | GPR84 (0.48) | GPR84FFAR1FFAR4TDP1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4105690-A | CONDENSATION | NOBEL HOECHST CHIMIE (FR) | 1978-08-08 | — | — | US | claimed |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-29 | — | — | US | disclosed |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-12-05 | — | — | US | disclosed |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-09 | — | — | US | disclosed |
| EP-4316503-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-07 | — | — | EP | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| WO-2020167958-A1 | METHODS FOR TREATING CHOLESTASIS | MIRUM PHARMACEUTICALS, INC. (US) | 2020-08-20 | — | — | WO | disclosed |
| US-7485421-B2 | Polyamide-oligonucleotide derivatives, their preparation and use | HOECHST GMBH (DE) | 2009-02-03 | — | — | US | disclosed |
| EP-1113021-B1 | Polyamide-oligonucleotide derivatives, their production and use | SANOFI AVENTIS DEUTSCHLAND (DE) | 2006-08-09 | — | — | EP | disclosed |
| US-6919441-B2 | Polyamide-oligonucleotide derivatives, their preparation and use | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-07-19 | — | — | US | disclosed |
| US-20050026817-A1 | Polyamide-oligonucleotide derivatives, their preparation and use | AVENTIS PHARMA DEUTSCHLAND GMBH (US) | 2005-02-03 | — | — | US | disclosed |
| US-20030203359-A1 | Polyamide-oligonucleotide derivatives, their preparation and use | HOECHST MARION ROUSSEL DEUTSCHLAND GMBH | 2003-10-30 | — | — | US | disclosed |
| WO-2002102762-A1 | NOVEL METHOD OF PREPARING HYDROXYARYLGLYCINES, ALCOXYARYLGLYCINES AND THE GLYCINATES THEREOF | UNIVERSIDAD COMPLUTENSE DE MADRID RECTORADO (ES) | 2002-12-27 | — | — | WO | disclosed |
| EP-0672677-B1 | Polyamide-oligonucleotide derivatives, their production and use | AVENTIS PHARMA GMBH (DE) | 2002-07-03 | — | — | EP | disclosed |
| EP-1113021-A2 | Polyamide-oligonucleotide derivatives, their production and use | Aventis Pharma Deutschland GmbH (DE) | 2001-07-04 | — | — | EP | disclosed |
| EP-0672677-A2 | Polyamide-oligonucleotide derivatives, their production and use | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-09-20 | — | — | EP | disclosed |
| US-4105690-A | CONDENSATION | NOBEL HOECHST CHIMIE (FR) | 1978-08-08 | — | — | US | disclosed |
| US-4105690-A | CONDENSATION | NOBEL HOECHST CHIMIE (FR) | 1978-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | GPR84 1715/4885FFAR1 3629/4885FFAR4 3700/4885 |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | GPR84 1715/4885FFAR1 3629/4885FFAR4 3700/4885 |
| US-20050026817-A1 | Polyamide-oligonucleotide derivatives, their preparation and use | POLRMT, POLR2H, POLN | GPR84 3886/4885FFAR1 2897/4885FFAR4 3249/4885 |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | VIP, IAPP, KRAS | GPR84 1585/4885FFAR1 3115/4885FFAR4 2114/4885 |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | KRAS, NRAS, HRAS | GPR84 1715/4885FFAR1 3629/4885FFAR4 3700/4885 |
| US-20030203359-A1 | Polyamide-oligonucleotide derivatives, their preparation and use | POLRMT, POLN, POLR2H | GPR84 4175/4885FFAR1 3558/4885FFAR4 3764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.